Efficacy and safety of nintedanib 1 docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO

被引：0
|
作者：
Grohe, C. [1 ]
Gleiber, W. [2 ]
Haas, S. [3 ,4 ]
Krueger, S. [5 ]
Schulze, M. [6 ]
Atz, J. [7 ]
Kaiser, R. [7 ]
机构：
[1] ELK Berlin, Dept Pneumol, Berlin, Germany
[2] Univ Hosp Frankfurt, Pneumol Allergol, Frankfurt, Germany
[3] FEK, Clin Haematol, Neumunster, Germany
[4] FEK, Clin Oncol & Nephrol, Neumunster, Germany
[5] Florence Nightingale Hosp, Dept Pulmonol Allergol Sleep Med & Resp Care, Dusseldorf, Germany
[6] Ambulante Onkol Ostsachsen, Zittau, Germany
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs Oncol, Ingelheim, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1505P
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [41] Association of clinico-pathological markers with longitudinal liquid biopsy (LB) results predicts outcome in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs)
    Bonanno, L.
    Zulato, E.
    Del Bianco, P.
    Bragadin, A. Boscolo
    Attili, I.
    Pavan, A.
    Nardo, G.
    Dal Maso, A.
    Ferro, A.
    Frega, S.
    Pasello, G.
    Fassan, M.
    Calabrese, F.
    Guarneri, V.
    Indraccolo, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S596 - S596
  • [42] Safety and Efficacy of Salvage Surgery after Treatment With Immune-Checkpoint Adjuvant Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric Study
    Schiavon, Marco
    Cannone, Giorgio
    Bertolaccini, Luca
    Gallina, Filippo Tommaso
    Pezzuto, Federica
    Lorenzoni, Giulia
    Facciolo, Francesco
    Spaggiari, Lorenzo
    Calabrese, Fiorella
    Rea, Federico
    Pasello, Giulia
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [43] Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection
    Zhao, Zhiting
    Hu, Ran
    Chen, Yan
    Zhou, Guoren
    Yu, Shaorong
    Feng, Jifeng
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 366 - 373
  • [44] Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis
    Tan, Kexin
    Wang, Aolin
    Zheng, Yumin
    Wang, Shuo
    Wang, Chao
    Li, Jia
    Lu, Xingyu
    Dong, Huijing
    Zheng, Jiabin
    Cui, Huijuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (01): : 196 - 203
  • [45] Re: Two centres' experience with lung cancer resection in patients with advanced non-small-cell lung cancer following treatment with immune checkpoint inhibitors: safety and clinical outcomes
    Mennecier, Bertrand
    Olland, Anne
    Mascaux, Celine
    Falcoz, Pierre-Emmanuel
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (06) : 1306 - 1307
  • [46] Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the first year of treatment: results of a non-interventional real-world study from Germany (ProGNOSE)
    Chaker, A.
    Pfaar, O.
    Foerster-Ruhrmann, U.
    Zeise, K.
    Wagenman, M.
    Gomez, L. De Prado
    Jacob-Nara, J.
    Hahn, M.
    Berns, M.
    Bretz, N.
    ALLERGOLOGIE, 2024, 47 (09)
  • [47] Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) plus docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy
    Grohe, C.
    Wehler, T. C.
    Henschke, S.
    Dittrich, I.
    Hammerschmidt, S.
    Aulmann, C.
    Dechow, T. N.
    Schiefer, C.
    von der Heyde, E.
    Schuette, W.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1072 - S1073
  • [48] Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)
    Bonanno, L.
    Zulato, E.
    Attili, I.
    Nardo, G.
    Pavan, A.
    Paola, D. B.
    Bragadin, A. Boscolo
    Pasello, G.
    Guarneri, V.
    Conte, P. F.
    Indraccolo, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1096 - S1096
  • [49] Identification of patients (pts) at high risk for early death with advanced or metastatic breast cancer (MBC), not receiving salvage treatment after 1st-line (1stL) therapy with trastuzumab (T) - Results of a prospective national non-interventional study (NIS) in Germany
    Jackisch, C.
    Schoenegg, W.
    Reichert, D.
    Welslau, M.
    Selbach, J.
    Harich, H-D
    Tesch, H.
    Keitel, S.
    Hinke, A.
    CANCER RESEARCH, 2016, 76
  • [50] Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) plus docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.
    Grohe, Christian
    Wehler, Thomas
    Henschke, Sven
    Dittrich, Ina
    Hammerschmidt, Stefan
    Aulmann, Christoph
    Dechow, Tobias
    Schiefer, Conrad
    Zander, Ingo
    Schuette, Wolfgang
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345